MASI Stock Analysis — Masimo Corporation
Sector: Healthcare
AI Verdict
You're paying up at 29.1x next year's earnings for a turnaround that hasn't shown up in the numbers yet, so unless Masimo's tech moat quickly reignites growth, this is expensive for the current fundamentals.
Competitive Moat
Masimo specializes in noninvasive patient monitoring devices, with a defensible position built on proprietary signal processing algorithms that enable accurate readings even in challenging clinical conditions. Its large installed base in hospitals creates switching costs for healthcare providers reliant on Masimo's ecosystem.
Summary
Masimo's proprietary pulse oximetry technology remains a clinical standard, but recent revenue contraction is raising questions about its growth story.
Where It Stands
Masimo trades at 29.1x forward earnings, well above the healthcare sector median of 22x, despite trailing revenue shrinking by 16.0% year-over-year.
Key Metrics
- Forward P/E: 29.1x
- Revenue Growth: -0.2%
- 52-Week High: $179.00
- 52-Week Low: $125.94
Analyst Consensus
6 Buy · 9 Hold · 0 Sell (15 analysts)
Bull Case
The 29.1x forward P/E implies the market expects a turnaround, betting on the stickiness of Masimo's technology in hospital settings.
Bear Case
With a 16.0% drop in revenue and a premium P/E, even a modest compression to the sector median (22x) would mean a 24% valuation hit if earnings don't rebound.
Catalyst to Watch
Watch for upcoming product launches or hospital contract renewals—if new wins don't reverse revenue declines, the premium valuation is at risk.